Abstract

Slow-release tablets containing 10 mg morphine sulphate (MST-1 Continus - Napp) have recently been introduced for the long-term management of patients with severe and intractable pain. Morphine is the analgesic of choice for severe pain in cancer,¹ but when given by mouth as an aqueous solution it needs to be taken every 4 hours. This solution is convenient for most patients, but those who are forgetful, live alone or have poor eyesight may find their therapy difficult to manage. The aim of a slow-release formulation of morphine is to allow a reduction in the frequency of analgesic administration, and given at bedtime it may also help patients who would otherwise wake in pain in the early morning.